Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MRNS)

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Business Wire 10 days ago

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Business Wire October 24, 2024

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

Business Wire October 17, 2024

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

Business Wire October 15, 2024

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Business Wire October 9, 2024

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire October 8, 2024

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Business Wire September 20, 2024

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

Business Wire September 12, 2024

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Business Wire September 10, 2024
View More News ››

Opinion & Analysis (NDAQ:MRNS)

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Streetwise Reports September 27, 2019
View More Opinion ››

Bullboard Posts (NDAQ:MRNS)

Market Perform Recommendation Issued On MRNS By JMP Securiti

Breaking News: $MRNS Market Perform Recommendation Issued On MRNS By JMP Securities2024-10-24 14:15:03 ET JMP Securities analyst issues...
whytestocks - October 24, 2024

DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmace

NEWS: $MRNS DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm...
whytestocks - July 29, 2024

Marinus Pharmaceuticals (MRNS) Securities Fraud: Contact Ber

NEWS: $MRNS Marinus Pharmaceuticals (MRNS) Securities Fraud: Contact Berger Montague To Discuss Your RightsPhiladelphia, Pennsylvania...
whytestocks - June 12, 2024

MRNS Investors Have Opportunity to Lead Marinus Pharmaceutic

Just In: $MRNS MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm |...
whytestocks - June 12, 2024

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts

JUST IN: $MRNS Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday | BenzingaTop Wall Street analysts changed...
whytestocks - April 17, 2024

Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Sto

JUST IN: $MRNS Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday? | BenzingaMonday,@Marinus...
whytestocks - April 15, 2024
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. is a Canada-based mineral exploration company focused on quality copper, gold and silver discoveries ...
View More »